According to data presented in a recent Lancet commentary, platform trials can evaluate 15-20 neurological treatments per decade, compared to just 3-5 using traditional randomized controlled trial methodology. This four-fold increase in research efficiency represents a significant advancement in addressing the urgent need for therapeutic breakthroughs in neurodegenerative diseases.
The improved efficiency stems from platform trials’ ability to test multiple interventions simultaneously within a single master protocol. Rather than conducting separate sequential studies for each potential treatment, researchers can evaluate candidates concurrently and dynamically adjust trial arms based on interim efficacy and safety data. This adaptive approach is particularly critical given the substantial global burden of neurological disease, which affects over 1 billion individuals and remains the world’s leading cause of ill health and disability.
Read the full article on GMJ Newsroom.
Was this article helpful?
